论文部分内容阅读
目的观察围绝经期子宫肌瘤应用小剂量米非司酮治疗的临床效果。方法对我院2009年12月至2012年1月收治的在围绝经期患有子宫肌瘤的患者56例应用米非司酮治疗的临床资料进行回顾性分析。结果 56例患者用药期间均闭经,停药6～12个月随访发现39例患者停药后绝经,占69.64%,10例月经稀少,11例停药后25周又恢复正常月经,但经量较前明显减少,5例患者停药后再次出现阴道出血,继续服用米非司酮3个月闭经。血红蛋白由治疗前为(88.46±12.63)g/L,经6个月治疗后为(112.47±16.50)g/L,治疗前后比较差异显著,子宫及子宫肌瘤体积治疗后均明显缩小,与治疗前比较差异有统计学意义(P<0.05)。结论对围绝经期患有子宫肌瘤的妇女采用小剂量米非司酮治疗效果显著,且无明显不良反应,值得推广应用。
Objective To observe the clinical effect of low dose mifepristone in perimenopausal uterine fibroids. Methods The clinical data of 56 cases treated with mifepristone in our hospital from December 2009 to January 2012 were analyzed retrospectively in patients with uterine fibroids in perimenopausal period. Results All 56 patients underwent amenorrhoea during the period of drug withdrawal. The follow-up of 6 to 12 months after drug withdrawal showed that 39 patients discontinued menopause after surgery, accounting for 69.64%, 10 cases were rare, and 11 cases returned to normal menstruation after 25 weeks. Significantly reduced compared with the previous, 5 patients relapsed after vaginal bleeding, mifepristone continue to take 3 months amenorrhea. Hemoglobin was (88.46 ± 12.63) g / L before treatment and (112.47 ± 16.50) g / L after 6 months of treatment, with significant difference before and after treatment. The volume of hemoglobin was significantly reduced after treatment, Before the difference was statistically significant (P <0.05). Conclusion The women with uterine fibroids in the perimenopausal period treated with low dose of mifepristone have a significant effect, and no obvious adverse reactions, which is worth popularizing and applying.